Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MAGEA4 (Melanoma antigen family A, 4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

EarlyCDT®-Lung

MAGE-A4 IHC 1F9 pharmDx (SK032)

EarlyCDT®-Lung

MAGE-A4 IHC 1F9 pharmDx (SK032)

›

MAGEA4 expression	Synovial Sarcoma	MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1	afamitresgene autoleucel Sensitive: A1 - Approval afamitresgene autoleucel Sensitive : A1
HLA-A*02 + MAGEA4 expression	Solid Tumor	HLA-A*02 + MAGEA4 expression	Solid Tumor	ADP-A2M4CD8 Sensitive: C3 – Early Trials ADP-A2M4CD8 Sensitive : C3	ADP-A2M4CD8 Sensitive: C3 – Early Trials ADP-A2M4CD8 Sensitive : C3
HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3
HLA-A*02 + MAGEA4 expression	Ovarian Cancer	HLA-A*02 + MAGEA4 expression	Ovarian Cancer	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3
MAGEA4 overexpression	Mucosal Melanoma	MAGEA4 overexpression	Mucosal Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3	afamitresgene autoleucel Sensitive: C3 – Early Trials afamitresgene autoleucel Sensitive : C3